Pomalidomide

POMALYST®

Overview

Pomalidomide is a cancer medicine that promotes an immune response to help slow tumor growth. It is used in combination with dexamethasone to treat people with relapsed/refractory multiple myeloma who have received at least two prior medicines to treat their myeloma (including a type of medicine known as a proteasome inhibitor and lenalidomide).

SparkCures ID 5
Developed By Celgene Corporation
Brand Name Pomalyst®
Generic Name Pomalidomide
Additional Names CC-4047, Actimid
Treatment Classifications

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

SparkCures Verified Accurate, up-to-date information. Learn more


Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

SparkCures Verified Accurate, up-to-date information. Learn more


Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources

There are no resources, links or videos to display for this treatment.